Creative Planning Boosts Stock Position in Allogene Therapeutics, Inc. (NASDAQ:ALLO)

Creative Planning raised its stake in Allogene Therapeutics, Inc. (NASDAQ:ALLO) by 108.7% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 61,396 shares of the company’s stock after purchasing an additional 31,984 shares during the period. Creative Planning’s holdings in Allogene Therapeutics were worth $172,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. CANADA LIFE ASSURANCE Co grew its stake in Allogene Therapeutics by 85.1% in the first quarter. CANADA LIFE ASSURANCE Co now owns 17,750 shares of the company’s stock valued at $79,000 after purchasing an additional 8,162 shares during the last quarter. Nisa Investment Advisors LLC grew its stake in shares of Allogene Therapeutics by 429.6% during the second quarter. Nisa Investment Advisors LLC now owns 10,767 shares of the company’s stock worth $25,000 after acquiring an additional 8,734 shares during the last quarter. Arizona State Retirement System grew its stake in shares of Allogene Therapeutics by 36.1% during the second quarter. Arizona State Retirement System now owns 40,915 shares of the company’s stock worth $95,000 after acquiring an additional 10,855 shares during the last quarter. Federated Hermes Inc. purchased a new stake in shares of Allogene Therapeutics during the second quarter worth about $29,000. Finally, Exchange Traded Concepts LLC grew its stake in shares of Allogene Therapeutics by 25.5% during the third quarter. Exchange Traded Concepts LLC now owns 60,675 shares of the company’s stock worth $170,000 after acquiring an additional 12,328 shares during the last quarter. Hedge funds and other institutional investors own 83.63% of the company’s stock.

Allogene Therapeutics Stock Performance

Shares of ALLO opened at $3.09 on Tuesday. Allogene Therapeutics, Inc. has a one year low of $2.01 and a one year high of $5.78. The stock has a market capitalization of $646.15 million, a price-to-earnings ratio of -1.98 and a beta of 0.84. The stock has a 50 day moving average price of $2.74 and a 200 day moving average price of $2.66.

Analyst Ratings Changes

ALLO has been the topic of a number of research analyst reports. Oppenheimer initiated coverage on Allogene Therapeutics in a research note on Thursday, August 8th. They set an “outperform” rating and a $11.00 price target on the stock. Truist Financial reaffirmed a “buy” rating and set a $14.00 target price (down previously from $17.00) on shares of Allogene Therapeutics in a report on Friday, August 9th. HC Wainwright reaffirmed a “buy” rating and set a $9.00 target price on shares of Allogene Therapeutics in a report on Friday. Canaccord Genuity Group decreased their target price on Allogene Therapeutics from $35.00 to $14.00 and set a “buy” rating for the company in a report on Thursday, August 8th. Finally, Citigroup lifted their target price on Allogene Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Three investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $9.96.

Allogene Therapeutics Profile

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).